PHARMACEUTICAL REVIEW

ISSN 2220-5187; We distribute and report the potential information of biological or life sciences – medicine, dentistry, pharmacy, nursing, veterinary, food, livestock, agriculture and public health. We publish the most current news, innovations, interviews and events (conferences, exhibitions, workshops, seminars). The professional bodies, business entrepreneurs, academic institutions and research organizations may contact us to market their events and business. We will help you to promote and advertise your products and services.


Leave a comment

ONE DAY WORKSHOP “SKILLS ENHANCEMENT OF CLINICAL PHARMACY” AT SCHOOL OF PHARMACY, UNIVERSITY OF LAHORE, ISLAMABAD

Islamabad (Dr. Syed Muzzammal Zaidi, Dr. Fawad Ali) One day workshop entitled “Skills Enhancement of Clinical Pharmacy” held on 22 December, 2010 (Wednesday) at School of Pharmacy, University of Lahore (Islamabad Campus), Pakistan. More than hundered persons participated and listened the presentations of scholars. This workshop was chaired by Dr. Taha Nazir (Associate Dean of School of Pharmacy, University of Lahore – Islamabad campus), hosted by Mr. Wajahat Latif (Director University of Lahore – Islamabad Campus) and chief guest Mrs. Amna Bibi (Hospital Pharmacist Poly Clinic Hospital, Islamabad). The distinguieshed speakers focused teh most current issues of clinical pharmacy as under;

1. Mr. Tahir Aqeel; Therapeutical significance of drug usage.

2. Mr. Muhammad Sabbir; Role of hospital Pharmacist in clinical setup.

3. Mr. Fawad Ali; Clinical pharmacy education, hospital pharmacy practice and regulation.

4. Dr. Taha Nazir; Professional challenges in clinical pharmacy practice

5. Mr. Muhammad Akhtar Abbas; Drug registration; legislation and procedure

 The participating pharmacist arrived from all discipline of pharmacy profession; community pharmacy, pharmaceutical marketing, research & development, ministry of Health, pharmaceutical institutions and industrial segment of this profession. The honorable guests; Mr. Adbul Sattar Sorani (Deputy Drug Controller), Mr. Zia Husnain (Deputy Drug Controller), Mr. Bilal Sorani has also shared the experiences. At the end of the workshop souvenirs were awarded to all speakers followed by refreshment.

Advertisements


Leave a comment

TOP 10 MEDICAL NEWS STORIES OF 2010 IN USA

By; Laird Harrison.

From Medscape Medical News

November 17, 2010 — Looking back, historians may mark 2010 as the most significant year for US medicine in decades. The healthcare reform legislation signed into law by President Barack Obama March 23 profoundly changes the way care is provided, and even if opponents succeed in repealing the legislation, the debate itself will shape the way we think about the issue for years to come.

The law didn’t come out of nowhere. Stresses and discontents in healthcare have been building for decades. Costs are rising at the same time that budgets are getting leaner. Most sophisticated tests are forcing physicians and patients to decide whether and how to treat diseases that previously went ignored. And new research calls old guidelines into question. Such tensions are reflected in nearly all the stories that surfaced as the most viewed by Medscape readers during the past year.

1. Cuts Loom in Medicare Reimbursement

The conflict over healthcare stems largely from a gap between the care we expect and the care we can afford. That gap is now threatening to undermine Medicare, which is scheduled for a 25% cut in reimbursements if Congress doesn’t act soon. The reduction would be triggered by the sustainable growth rate formula used for setting physicians’ pay. It could force many physicians to drop Medicare, which would send shockwaves throughout the system, as Medicare patients make up about a third of the practices of 70% of physicians. Almost no one wants to see the cuts take place, but the Congressional Budget Office estimates that keeping reimbursements at current levels through 2020 will cost $276 billion. Under pressure to reduce the national deficit, Congress so far hasn’t been able to agree on a source for that much money. Throughout 2010, it kept delaying the cut with a series of short-term fixes. What’s likely to happen next? More delays. With the Republicans controlling one chamber of Congress and the Democrats the other, gridlock could doom long-term “doc fix” legislation for the coming year.

2. Healthcare Reform

Whatever else you might say about healthcare reform, it’s a big deal. The most comprehensive overhaul of the nation’s healthcare system at least since Medicare, the Affordable Care Act seeks to dramatically expand the number of people who can afford healthcare. It does that by subsidizing the cost for those who can’t afford it, penalizing those who refuse to buy it, and limiting the cases in which insurers can deny coverage. Among scores of other provisions, it boosts pay for primary care physicians, encourages compensation based on quality of care, and bars copayments for most preventive services. As the law is implemented, questions about these and other provisions are cropping up. For starters, do we have enough physicians, nurses and other healthcare workers to care for an estimated additional 32 million insured? Also, who will make up the difference if fewer copayments are collected? These questions and more are certain to arise as legislators critical of the law attack it with renewed vigor.

3. New Guidelines for Prostate Cancer Screening

The advent of better tests — such as prostate-specific antigen (PSA) screening — can in some cases save lives with early treatment. However, these tests can also pose new dilemmas, as the American Cancer Society (ACS) emphasized on March 3 when it updated its prostate cancer screening guidelines. The test picks up benign disease in addition to cancer, and it can’t distinguish between aggressive and mild forms of the disease, the ACS pointed out. In some cases, PSA screening has led to expensive and invasive treatments in patients who might never have experienced symptoms. So the ACS is calling on physicians to spend more time counseling patients about their options (despite the difficulty of billing for such counseling). The PSA controversy intensified when the scientist who discovered PSA in 1970, Richard Ablin, PhD, from the University of Arizona College of Medicine in Tucson, said categorically that the test should not be used to screen all men older than 50 years. That’s a direct contradiction of the ACS guidelines. Controversy about the value of PSA testing continued when results of studies on both the effectiveness of the test and on chemoprevention were reported.

4. Whistle-Blowing Nurses Prosecuted

Healthcare is not without its scandals, perhaps the biggest of which in 2010 was the criminal prosecution of 2 nurses who reported Rolando Arafiles Jr, MD, at Winkler County Memorial Hospital in Kermit, Texas, to the Texas Medical Board for low quality of care. As it turned out, Dr. Arafiles was friends with the local sheriff, who arrested Anne Mitchell, RN, and Vickilyn Galle, RN, for misuse of official information — a third-degree felony. Prosecutors dropped charges against Galle, and a jury quickly acquitted Mitchell, but the hospital fired both of them. Subsequently the medical board charged Dr. Arafiles with 9 instances of substandard care. In one charge, it accused him of suturing the rubber from suture-kit scissors to a patient’s torn and broken thumb in an unorthodox attempt to stabilize the digit. The nurses sued Dr. Arafiles and the hospital in federal court for, among other things, violating their freedom of speech, but dropped the suit after the defendants agreed to pay them $750,000 as part of a settlement.

5. Centers for Medicare and Medicaid Services Appointment Stirs Controversy

When Obama nominated Donald Berwick, MD, administrator of the Centers for Medicare and Medicaid Services, critics pointed to comments Dr. Berwick had made in admiration of Britain’s National Health Service and in calling for the redistribution of wealth “from the richer among us to the poorer and less fortunate.” However, Dr. Berwick has a track record of success in helping many organizations to solve practical healthcare problems, which earned him support among groups of physicians, consumers, businesses, and insurers, including the American Medical Association. Facing opposition in the Senate, Obama took advantage of a loophole allowing him to appoint Dr. Berwick without the need for confirmation while the Senate was in recess.

6. Revised Diabetes Guidelines Highlight A1c

Screening technology popped up in the news again in December 2009 when the American Diabetes Association published new clinical practice recommendations. (Despite the timing, the news story quickly moved to into the top 10 most-read topics on Medscape.) The guidelines promote the use of the hemoglobin A1c (A1c) as a faster, easier diagnostic test that could help reduce the number of undiagnosed patients and better identify patients with prediabetes. A1c measures average blood glucose levels for a period of up to 3 months. Previously it was used only to evaluate diabetic control with time, but because it doesn’t require fasting, A1c testing will encourage more people to get tested, leading to treatments and lifestyle changes that could prevent the worst effects of the disease, the American Diabetes Association said.

7. Calcium Boosts Heart Attack Risk

Prevention guidelines also made headlines when a large study found that calcium supplements taken without vitamin D may increase the risk for heart attack as much as 30%. Researchers reported the finding online July 29 in BMJ, based on their meta-analysis of 15 randomized trials with up to 11,921 participants. Most guidelines for osteoporosis currently recommend the supplements, despite relatively small benefits in bone health, but senior author Dr. Ian R. Reid, from the University of Auckland in New Zealand, said that in most cases, “discontinuation of calcium would seem appropriate.” The study raised many questions, such as why calcium could have this effect during a relatively short period of time. Pending further research, some experts advised eating foods high in calcium, rather than taking supplements.

8. Volunteers Moved by Haiti Earthquake

When an earthquake devastated Haiti on January 12, thousands of physicians and other healthcare professionals started packing their black bags and booking airplane tickets. Experts at a webinar held by the American Medical Association warned against a rush, pointing out that volunteers without the proper preparation could hinder relief efforts. During the next 10 days, however, the need for specialists in emergency medicine, orthopaedic surgery, and neurology became increasingly clear. By the end of the month, more than 600 relief organizations were working in Haiti, and the American Medical Association established a physician registry for volunteers.

9. FDA Warns Against Quinine for Cramps

What do you do when no one pays attention to your guidelines? Issue them again. That was the approach taken by the US Food and Drug Administration (FDA) July 8 after it noticed that most of the quinine being prescribed in the United States isn’t for the approved indication — uncomplicated malaria — but, rather, for leg cramps. Taking quinine (marketed by AR Scientific as Qualaquin) may result in serious and life-threatening hematologic adverse effects, the FDA said. The statement reiterated a 2006 warning about the off-label use of this drug that apparently fell on deaf ears.

10. Task Force Revises Mammography Guidelines

For those who follow such things, 2010 also may also be remembered as the year of the mammoth mammography muddle. On November 17, 2009, the US Preventive Services Task Force called for an end to routine mammography for women younger than 50 years, citing a lack of evidence for benefits in women that young, sparking outrage from screening advocates. On January 6, 2010, however, the American College of Radiology and the Society of Breast Imaging directly contradicted the task force, recommending routine mammography at age 40 years and older. The debate got further fuel from a Swedish epidemiological study of breast cancer, touted as the largest ever, which found that mammography produced a 26% reduction in mortality from breast cancer in women aged 40 to 49 years. Another study from Norway found that the benefits from mammography screening were modest, however, and an accompanying editorial highlighted the delicate balance between potential benefit and potential harm, concluding that the decision to undergo mammography is “a close call.”


Leave a comment

POTENTIAL INTERACTION BETWEEN CLOPIDOGREL AND PROTON PUMP INHIBITORS

By; Patricia A. Howard; James L. Vacek

From American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions. Posted: 03/02/2010; Am J Cardiovasc Drugs. 2009;9(6):353-359. © 2009 Adis Data Information BV

 Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation. The antiplatelet action of clopidogrel is felt to be of critical importance for the reduction of abrupt thrombotic occlusion of stents, particularly with drug-eluting devices. When clopidogrel is used alone or in combination with aspirin (acetylsalicylic acid), the benefits of antiplatelet therapy must be weighed against the potential for serious bleeding, particularly gastrointestinal (GI) bleeds. To minimize the risk of GI injury, proton pump inhibitors (PPIs) are considered the drugs of choice. However, a growing body of evidence suggests that PPIs may adversely interact with clopidogrel, diminishing the antiplatelet effect. Although the current evidence remains controversial, the potential for increased risk of thrombotic complications warrants cautious use of this drug combination until further research can determine the extent of this interaction and whether it is a drug-class effect.

Clopidogrel is a potent antiplatelet drug with actions mediated through irreversible inhibition of the platelet ADP receptor, P2Y12. Clopidogrel is widely used to prevent thrombotic complications in patients with acute coronary syndromes (ACS), with or without percutaneous coronary intervention (PCI), and is particularly effective for patients with drug-eluting devices. Clopidogrel monotherapy has been associated with an increased risk of bleeding. Several clinical trials have shown that the risk of bleeding, especially gastrointestinal (GI) bleeding, is further increased in high-risk coronary patients who often require dual antiplatelet therapy with both clopidogrel and aspirin (acetylsalicylic acid). Guidelines for the prevention or treatment of antiplatelet drug-associated GI injury recommend proton pump inhibitors (PPIs) as first-line agents.

Recently, concerns have been raised over a potential drug interaction between clopidogrel and PPIs that may diminish the antiplatelet activity of clopidogrel. Because of the serious clinical implications of a decreased antiplatelet response in high-risk coronary patients, reports of this potential interaction with PPIs must be further explored.


Leave a comment

FDA RESTRICTS ROSIGLITAZONE; EMA PULLS THE PLUG

By; Shelley Wood, Lisa Nainggolan, Sue Hughes

From Heartwire > Alerts. Posted: 09/23/2010

 September 23, 2010 (Updated September 24, 2010) (Silver Springs, Maryland and London, United Kingdom) — The US FDA has decided that rosiglitazone (Avandia, GlaxoSmithKline) can remain available, but only under a very stringent restricted-access program. However, the European Medicines Agency (EMA) has recommended the suspension of the marketing authorizations for all rosiglitazone-containing antidiabetes medications licensed in the EU–Avandia, Avandamet, and Avaglim.

“These medicines will stop being available in Europe within the next few months,” the agency said in a statement. “Patients are advised not to stop their treatment without speaking to their doctor. Doctors should stop prescribing rosiglitazone-containing medicines, and patients taking rosiglitazone-containing medicines should be reviewed in a timely manner to amend their treatment.”

As previously reported by heartwire , rosiglitazone has been under mounting scrutiny both in the US and Europe, culminating in an FDA advisory hearing where 12 out of 33 panel members voted to recommend removal of the drug from the US market and an additional 10 panelists voted to recommend that rosiglitazone stay on the market, but with severe restrictions on its use.

In response to both the FDA and EMA statements issued today, GlaxoSmithKline said that the EMA has “stated that the suspension will remain in place unless convincing data are provided that identify a group of patients in whom the benefits of the medicine outweigh its risks.” In the US, all rosiglitazone-containing medicines will remain available with additional safety labeling and restrictions for use, which includes the FDA requiring a risk evaluation and mitigation strategy (REMS) program with additional measures to ensure the safe use of the medicine.

At a telephone press briefing, EMA senior medical officer Prof Hans-Georg Eichler explained that the agency had now concluded that the benefits of rosiglitazone no longer outweighed its risks, so that is why it has decided to suspend the drug. He said the recommendation for suspension would now be passed onto the European Commission, who will make a formal legally binding decision. That would happen in the next couple of weeks. The drug would then not be available anymore. Letters would go out to advise doctors to discuss with patients on a case-by-case basis the best therapeutic alternatives to use.

Eichler noted that a suspension is different from a withdrawal. “Suspension can be a temporary measure. It can be lifted if a company comes up with convincing and robust data that rosiglitazone benefits outweigh its risks in certain populations.”

Asked about the safety profile of pioglitazone, Dunder noted that “there is large probability that the cardiovascular safety of pioglitazone is different from rosiglitazone, and we have biological plausibility to confirm that.” She added that the risk of bladder cancer with pioglitazone has now been raised and is being investigated. “For the time being, there is absolutely no reason to think that bladder cancer is a real risk, but a question has been raised about this, and we are consistently reviewing this with the FDA.”

At an FDA telephone briefing, FDA Commissioner Dr Margaret Hamburg explained that the REMS restriction on rosiglitazone will allow new patients access to the drug only if they are unable to achieve glycemic control using other medications and, in consultation with their healthcare professional, decide not to take pioglitazone for medical reasons. Current users of rosiglitazone will be able to continue using the medication, again through a REMS program, only if they appear to be benefiting from it and they acknowledge that they understand these risks. Doctors will have to attest to and document their patients’ eligibility; patients will have to review statements describing the cardiovascular safety concerns. The FDA’s explanation of its action is also detailed in a “Perspective” published online earlier today in the New England Journal of Medicine.

The agency anticipates that the REMS will limit use of rosiglitazone significantly. Hamburg estimated that about 600 000 patients are currently taking rosiglitazone in the US, but this number is now expected to “fall significantly,” she said. However, the REMS programs will take several months to set up. The rosiglitazone label will also be strengthened to include even stronger warnings of cardiac risk, but Hamburg said that because new label warnings are not always read, the “significant questions” about the drug’s cardiovascular safety justified stronger measures to support good clinical decision making and protect patients–hence the REMS program.

Echoing the EMA’s comments on the different action in Europe, Hamburg said both the FDA and EMA had reached similar conclusions about the safety of rosiglitazone, but the different actions taken reflected different tools available in Europe and the US. She added: “We [the FDA and EMA] are taking somewhat different strategies, but both are trying to ensure the goal of safety.” Dr Janet Woodcock (director, FDA Center for Drug Evaluation and Research) elaborated: “We have a signal of increased cardiovascular risk with rosiglitazone from the meta-analyses, but there is still considerable uncertainty about the existence and magnitude of that risk. Data from randomized studies have not provided enough reassurance that the drug meets the required standard of safety. Therefore, as a matter of prudence, we have decided to restrict access to the drug. But we have heard very clearly from patients and doctors that some patients were unable to tolerate other diabetes medications and this drug was effective for them. Our approach will enable those patients to continue taking rosiglitazone as long as they are fully informed of the risks.”


Leave a comment

GEMTUZUMAB VOLUNTARILY WITHDRAWN FROM US MARKET

By; Roxanne Nelson

From Medscape Medical News. Posted: 06/21/2010

 June 21, 2010 — Pfizer Inc has announced that it will be discontinuing commercial availability of gemtuzumab ozogamicin (Mylotarg; Wyeth) for the treatment of relapsed acute myeloid leukemia (AML), in the United States. It will also voluntarily withdraw the new drug application for gemtuzumab, effective October 15, 2010.

The action is at the request of the US Food and Drug Administration (FDA) after results from a recent clinical trial raised new concerns about the drug’s safety profile and also failed to demonstrate clinical benefit to patients currently enrolled in trials.

“Mylotarg was granted an accelerated approval to allow patient access to what was believed to be a promising new treatment for a devastating form of cancer,” said Richard Pazdur, MD, director, Office of Oncology Drug Products, part of FDA’s Center for Drug Evaluation and Research, in a statement. “However, a confirmatory clinical trial and years of postmarketing experience with the product have not shown evidence of clinical benefit in patients with AML.”

Gemtuzumab was approved on May 17, 2000, under the FDA’s accelerated approval program, for the treatment of patients 60 years and older with recurrent AML, who were not considered candidates for other chemotherapy. The initial approval was based on the surrogate endpoint of response rate that was observed in 142 patients with AML across 3 clinical trials.

However, hepatotoxicity; specifically severe veno-occlusive disease; and hypersensitivity reactions including anaphylaxis, infusion reactions, and pulmonary events were observed after initial approval. This resulted in a black-box warning issued less than a year after its approval. A confirmatory, post-approval clinical trial was begun in 2004, per FDA guidelines for accelerated approval. The randomized phase 3 comparative controlled trial (SWOG S0106) combined gemtuzumab with the chemotherapeutic agents daunorubicin and cytosine arabinoside vs chemotherapy alone in 627 patients younger than 61 years.

The trial was designed to determine whether adding gemtuzumab to standard chemotherapy demonstrated an improvement in survival time for patients with AML, but it was halted early when no benefit was observed. A greater number of deaths occurred in the cohort who received gemtuzumab vs those receiving chemotherapy alone. Among patients who were evaluable for early toxicity, the fatal induction toxicity rate was significantly higher in the combination therapy group vs the group receiving chemotherapy alone (16/283 = 5.7% vs 4/281 = 1.4%; P = .01).

“We are disappointed that the study did not confirm the clinical benefit of Mylotarg,” said Mace Rothenberg, MD, senior vice president of clinical development and medical affairs for Pfizer Oncology Business Unit, in a release. “Our primary concern is for patients who suffer from AML, which remains a very serious and difficult-to-treat disease with limited treatment options. We advise patients to contact their physicians for further information.”

As a result of this action, gemtuzumab will no longer be commercially available to new patients. Patients who are currently receiving the drug may complete their therapy, after consulting with their physicians. Healthcare professionals should inform all patients receiving gemtuzumab of the potential adverse events associated with the agent, the FDA release notes.

All future use of gemtuzumab in the United States will require submission of an investigational new drug application to the FDA. Pfizer states that it is currently working the health authorities outside of the United States and will keep patients, regulatory authorities, investigators, and clinicians informed about FDA actions and appropriate next steps for gemtuzumab. More information is available on the FDA’s MedWatch .

Any adverse events associated with gemtuzumab should be communicated to the FDA’s MedWatch reporting program by telephone at 1-800-FDA-1088; by fax 1-800-FDA-0178, online at http://www.accessdata.fda.go v/scripts/medwatch, or by mail to 5600 Fishers Lane, Rockville, Maryland 20852-9787.


Leave a comment

ABBOTT WITHDRAWS SIBUTRAMINE FROM MARKET

By; Robert Lowes

From Medscape Medical News. Posted: 10/08/2010

 October 8, 2010 — Abbott Laboratories has withdrawn the obesity drug sibutramine (Meridia) from the market in light of clinical trial data pointing to an increased risk for stroke and myocardial infarction, the US Food and Drug Administration (FDA) announced today.

The agency asked Abbott Laboratories to pull the drug from the market after it evaluated data from a postmarketing study of the drug’s cardiovascular safety. The study, called the Sibutramine Cardiovascular Outcomes Trial (SCOUT), demonstrated a 16% increase in the risk for serious cardiovascular events such as nonfatal heart attack, nonfatal stroke, the need for resuscitation after the heart stopped, and death in a cohort of patients given sibutramine compared with another given a placebo.

In September, an FDA advisory panel reviewed the SCOUT results, with half of the members in favor of withdrawing sibutramine and the other half recommending stricter access to the drug and tougher label warnings.

Following the advisory panel vote, the FDA concluded that the cardiovascular risks posed by sibutramine outweigh the modest weight loss observed with the drug, which the agency had approved in 1997.

At a press conference today, John Jenkins, MD, director of the Office of New Drugs at the FDA’s Center for Drug Evaluation and Research, said that roughly 100,000 people in the United States are currently taking sibutramine.

The FDA is advising physicians to stop prescribing sibutramine and for patients to stop taking it and talk to their healthcare provider about alternative weight-loss regimens. The agency does not know of any withdrawal syndrome associated with the drug, according to Dr. Jenkins.

Dr. Jenkins also said he is not aware of any long-term consequences for patients who stop taking the drug. The cardiovascular events observed in SCOUT, he said, probably stem from sibutramine increasing blood pressure and heart rate. These adverse effects disappear once the drug is withdrawn.

In the wake of the sibutramine decision, there are still a limited number of FDA-approved drugs for losing weight, said Mary Parks, MD, director of the agency’s Division of Metabolic and Endocrine Drug Products, at today’s press conference. Prescription drugs for short-term weight loss include phentermine and diethylpropion. Orlistat is available in both an over-the-counter form (Alli; GlaxoSmithKline) and prescription form (Xenical; Hoffman-La Roche) at a higher dose, Dr. Parks added. Last May, the FDA revised the label for both versions of orlistat to warn about rare cases of severe liver injury associated with the drug.

Dr. Jenkins suggested Friday that the nation would benefit from more weight-loss drugs. “We’re still very committed to working with (manufacturers) to help them to develop and gain approval of safe and effective drugs to help patients manage weight,” Dr. Jenkins said. “Obesity is a serious health problem. More information about today’s announcement is available on the FDA’s Web site.

In a related action, the FDA warned consumers today not to use a weight-loss product called Slimming Beauty Bitter Orange Slimming Capsules, sold over the Internet, because they contain sibutramine. The drug is not listed on the product label.

To report adverse events related to sibutramine or Slimming Beauty capsules, contact MedWatch, the FDA’s safety information and adverse event reporting program, by telephone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at http://www.fda.gov/medwatch, or by mail to MedWatch, FDA, 5600 Fishers Lane, Rockville, Maryland 20852-9787.


Leave a comment

ELECTION 2011 (PUNJAB PROVINCE) AND 2ND NNUAL MEETING OF PHARMACIST FEDERATION OF PAKISTAN

Lahore (Dr. Tahir Aziz Mughal, Fayaz Ahmad Faizi) A very successful meeting of Pharmacist Federation of Pakistan held on at Mansoora, Lahore. The pharmacists from all over the Pakistan and every field of the pharmacy discipline have participated in meeting. The meeting was chaired by Dr. Addul Aleem Khan and conducted by Mr. Fayaz Ahmad Faizi. Executives of Pharmacist Federation presented the reports of their area for the year 2010 and decided the goals for the year 2011. They also have disclosed that the membership of Pharmacist Federation is online, free and open for everyone at http://www.pharmacistfed.pk/master/Members.aspx.  

There also an electoral procedure conducted for Punjab provinces; session 2011 as mention in their constitution. The new body elected is as under;

Malik Irshad Husain (president Punjab), Mr. Fazya Ahmad Faizi General Secretary Punjan, Dr. Syed Muzzammil Masood Zaidi (president Islamabad), Hafiz Muhammad Abdullah (president Bhakkar), Mr. Khursheed Alam (president: Rawalpindi), Aziz Ur Rehman (president Sargodha), Dr. Shaoib Zafar (president Faisalabad division) Malik Muhammad Waheed (President Jehlum), Muhammad Bib Ibrahim (president Multan) and Asaad Imran (president: Lahore).